How many insider trades does FilingIQ track for BBOT?

FilingIQ tracks 27 Form 4 insider transactions for BBOT (BridgeBio Oncology Therapeutics, Inc.), covering filings from Aug 11, 2025 onwards. 12 of those were filed in the last 90 days.

Are BBOT insiders net buyers or net sellers?

Across the full Form 4 history for BBOT, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BBOT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BBOT in?

BridgeBio Oncology Therapeutics, Inc. (BBOT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $730.30M.

BBOT insider trading

NasdaqGM Healthcare

BridgeBio Oncology Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$730.30M

About BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.

Company website: bbotx.com

BBOT insider activity at a glance

FilingIQ has scored 27 insider transactions for BBOT since Aug 11, 2025. The most recent filing in our index is dated May 10, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live BBOT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for BBOT?: FilingIQ tracks 27 Form 4 insider transactions for BBOT (BridgeBio Oncology Therapeutics, Inc.), covering filings from Aug 11, 2025 onwards. 12 of those were filed in the last 90 days.
Are BBOT insiders net buyers or net sellers?: Across the full Form 4 history for BBOT, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BBOT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BBOT in?: BridgeBio Oncology Therapeutics, Inc. (BBOT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $730.30M.

Methodology & sources

Every BBOT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.